

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-38. (Cancelled).

39. (Previously presented) A recombinant nucleic acid comprising a nucleotide sequence encoding a 7:20 cis-acting ribozyme, a trans-acting ribozyme, and a 18:7 cis-acting ribozyme, wherein said 7:20 cis-acting ribozyme comprises the sequence of SEQ ID NO:53 from position 7 to position 91, and wherein said 18:7 cis-acting ribozyme comprises the sequence of SEQ ID NO:53 from position 110 to position 190.

40-41. (Cancelled)

42. (Previously presented) The recombinant nucleic acid of claim 39, wherein said recombinant nucleic acid comprises an origin of replication.

43. (Previously presented) The recombinant nucleic acid of claim 39, wherein said recombinant nucleic acid encodes more than one trans-acting ribozyme.

44. (Previously presented) The recombinant nucleic acid of claim 43, wherein the trans-acting ribozymes are targeted to different sites on the same target-RNA.

45. (Previously presented) The recombinant nucleic acid of claim 43, wherein the trans-acting ribozymes are targeted to different target-RNAs.

46. (Previously presented) The recombinant nucleic acid of claim 39, wherein said recombinant nucleic acid encodes more than one ribozyme cassette.

47. (Previously presented) The recombinant nucleic acid of claim 39, wherein said recombinant nucleic acid encodes at least two different ribozymes cassettes.

48. (Previously presented) The recombinant nucleic acid of claim 39, wherein said recombinant nucleic acid encodes more than one copy of a ribozyme cassette.

49. (Previously presented) The recombinant nucleic acid of claim 39, wherein said trans-acting ribozyme is targeted to a transcript selected from the group consisting of: pol II, HBV, pol III, RB, IGF1, SH, pol I, HPV, C3, C9, B2, Tel, TGFJ, CAT, PpaRI, p4501E1, AR, and SF1 transcripts.

50. (Previously presented) The recombinant nucleic acid of claim 39, wherein said nucleotide sequence encodes a hairpin loop.

51. (Previously presented) The recombinant nucleic acid of claim 39, wherein said nucleotide sequence encodes multiple ribozyme cassettes linked together by at least 4 nucleotides.

52. (Previously presented) The recombinant nucleic acid of claim 39, wherein said nucleic acid further comprises a tissue-specific promoter is selected from the group consisting of a K4 promoter, K7 promoter, K13 promoter and albumin promoter.

53. (Previously presented) An isolated cell containing a recombinant nucleic acid comprising a nucleotide sequence encoding a 7:20 cis-acting ribozyme, a trans-acting ribozyme,

and a 18:7 cis-acting ribozyme, wherein said 7:20 cis-acting ribozyme comprises the sequence of SEQ ID NO:53 from position 7 to position 91, and wherein said 18:7 cis-acting ribozyme comprises the sequence of SEQ ID NO:53 from position 110 to position 190.

54. (Previously presented) A virion comprising a recombinant nucleic acid comprising a nucleotide sequence encoding a 7:20 cis-acting ribozyme, a trans-acting ribozyme, and a 18:7 cis-acting ribozyme, wherein said 7:20 cis-acting ribozyme comprises the sequence of SEQ ID NO:53 from position 7 to position 91, and wherein said 18:7 cis-acting ribozyme comprises the sequence of SEQ ID NO:53 from position 110 to position 190.

55. (Previously presented) A liposome composition comprising a recombinant nucleic acid comprising a nucleotide sequence encoding a 7:20 cis-acting ribozyme, a trans-acting ribozyme, and a 18:7 cis-acting ribozyme, wherein said 7:20 cis-acting ribozyme comprises the sequence of SEQ ID NO:53 from position 7 to position 91, and wherein said 18:7 cis-acting ribozyme comprises the sequence of SEQ ID NO:53 from position 110 to position 190.